二甲双胍和他汀类药物已证实能够预防癌症。该This study assessed whether the effect of metformin on prostate cancer (PCa) incidence varied by statin use among type 2 diabetic patients.该该 研究旨在评估他汀类药物的使用是否改变二甲双胍对2型糖尿病患者前列腺癌发病率的影响。研究对象包括5,042名男性无癌症病史的2型糖尿病患者，均来自1999年至2005年间退伍军人管理局医疗保健系统，且仅用二甲双胍或磺酰脲类作为降糖药物。 Cox proportional hazard analyses were conducted to assess the differential hazard ratio (HR) of PCa due to metformin by statin use versus sulfonylurea use, where propensity scores of metformin and statin use were adjusted to account for imbalances in baseline covariates across medication groCox比例风险分析用以评估二甲双胍与他汀药物联合使用和单用磺脲类药物的患者前列腺癌患病的危险比。并对使用二甲双胍和他汀类药物的倾向分数进行校正，以消除药物治疗组之间协变量基线水平的不平衡。 RESULTS Mean follow-up was ∼5 years, and 7.5% had a PCa diagnosis. 研究平均随访5年，有7.5%的2型糖尿病患者诊断为前列腺癌。 Statin use modified the effect of metformin on PCa incidence ( P < 0.0001).他汀类药物的使用能够改进二甲双胍对前列腺癌发病率的影响（P <0.001）。二甲双胍显著性降低服用他汀类药物患者的前列腺癌发病率（Metformin was associated with a significantly reduced PCa incidence among patients on statins (HR 0.69 [95% CI 0.50–0.92]; 17 cases/533 metformin users vs. 135 cases/2,404 sulfonylureas users) and an increased PCa incidence among patients not on statins (HR 2.15 [1.83–2.52]; 22 cases/175 metformin users vs. 186 cases/1,930 sulfonylureas users).（HR 0.69 [95％CI为0.50-0.92]; 17 例前列腺癌患者/533例二甲双胍使用者与135例前列腺癌患者/ 2,404磺脲类药物使用者之比），未服用他汀类药物的患者前列腺癌发病率增加（HR2.15 [1.83-2.52]; 22 例/175二甲双胍使用者与186例/ 1930磺脲类服用者之比）。同时服用二甲双胍和他汀类药物者相对于未服用此两种药物者的前列腺癌发病率的危险比为0.32（0.25-0.42）。该研究结论是联合使用The HR of PCa incidence for those taking metformin and statins versus those taking neither medication was 0.32 (0.25–0.42).同时服用同时CONCLUSIONS Among men with type 2 diabetes, PCa incidence among metformin users varied by their statin use.他汀类药物可以使服用二甲双胍的2型糖尿病患者的前列腺癌发病率发生改变。The potential beneficial influence on PCa by combination use of metformin and statin may be due to synergistic effects.二甲双胍和他汀类药物联合使用对前列腺癌的潜在益处可能归因于两者的协同效应。